rilogrotug

Home
Ligands
rilogrotug

GtoPdb Ligand ID: 13664

Synonyms: AV380

Comment: Rilogrotug (AV-380; AVEO Pharmaceuticals) is a humanized anti-growth differentiation factor 15 (GDF15) IgG1κ monoclonal antibody. Blocking GDF15 binding to its receptor GFRAL is recognised to induce anti-cachexia efficacy in preclinical models and is proposed as a therapeutic modality to treat cachexia that is caused by over-expression of GDF15 (e.g. cancer-associated cachexia) [1,3].

Data in support of clinical efficacy from a phase 2 trial in patients with cancer-associated cachexia who were administered Pfizer's anti-GDF15 monoclonal, ponsegromab, were published in late 2024 [2].

References
1. Breit SN, Brown DA, Tsai VWW. (2024) GDF15 research from bench to bedside. Cancer Cell, 42 (11): 1823-1824. [PMID:39454578]
2. Groarke JD, Crawford J, Collins SM, Lubaczewski S, Roeland EJ, Naito T, Hendifar AE, Fallon M, Takayama K, Asmis T et al.. (2024) Ponsegromab for the Treatment of Cancer Cachexia. N Engl J Med, 391 (24): 2291-2303. [PMID:39282907]
3. Huang Y, Wang J, Wei X, Zhang H, Shang W, Zhang X, Zhai L, Chen X, Li H, Qin S. (2024) GB18-06, a nanobody targeting GDF15, effectively alleviates weight loss and restores physical function in cachexia models. MAbs, 16 (1): 2416453. [PMID:39400041]
4. Lerner L, Abbott S, Bai A, Chen T, Chiu MI, Liu Q, Poling L, Tao N, Weiler S, Weng Z et al.. (2014) Anti-gdf15 antibodies. Patent number: WO2014100689A1. Assignee: Aveo Pharmaceuticals, Inc.. Priority date: 20/12/2013. Publication date: 26/06/2014.

References

1. Breit SN, Brown DA, Tsai VWW. (2024)
GDF15 research from bench to bedside.
Cancer Cell, 42 (11): 1823-1824. [PMID:39454578]

2. Groarke JD, Crawford J, Collins SM, Lubaczewski S, Roeland EJ, Naito T, Hendifar AE, Fallon M, Takayama K, Asmis T et al.. (2024)
Ponsegromab for the Treatment of Cancer Cachexia.
N Engl J Med, 391 (24): 2291-2303. [PMID:39282907]

3. Huang Y, Wang J, Wei X, Zhang H, Shang W, Zhang X, Zhai L, Chen X, Li H, Qin S. (2024)
GB18-06, a nanobody targeting GDF15, effectively alleviates weight loss and restores physical function in cachexia models.
MAbs, 16 (1): 2416453. [PMID:39400041]

4. Lerner L, Abbott S, Bai A, Chen T, Chiu MI, Liu Q, Poling L, Tao N, Weiler S, Weng Z et al.. (2014)
Anti-gdf15 antibodies.
Patent number: WO2014100689A1. Assignee: Aveo Pharmaceuticals, Inc.. Priority date: 20/12/2013. Publication date: 26/06/2014.